- Home
- PBYI vs CGEN Comparison
PBYI vs CGEN Comparison
Compare PBYI & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- CGEN
- Stock Information
- Founded
- PBYI 2010
- CGEN 1993
- Country
- PBYI United States
- CGEN Israel
- Employees
- PBYI N/A
- CGEN N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PBYI Health Care
- CGEN Health Care
- Exchange
- PBYI Nasdaq
- CGEN Nasdaq
- Market Cap
- PBYI 167.3M
- CGEN 167.4M
- IPO Year
- PBYI N/A
- CGEN 2000
- Fundamental
- Price
- PBYI $3.24
- CGEN $1.64
- Analyst Decision
- PBYI Strong Buy
- CGEN
- Analyst Count
- PBYI 1
- CGEN 0
- Target Price
- PBYI $7.00
- CGEN N/A
- AVG Volume (30 Days)
- PBYI 347.1K
- CGEN 264.8K
- Earning Date
- PBYI 07-31-2025
- CGEN 08-05-2025
- Dividend Yield
- PBYI N/A
- CGEN N/A
- EPS Growth
- PBYI 143.51
- CGEN N/A
- EPS
- PBYI 0.77
- CGEN N/A
- Revenue
- PBYI $232,709,000.00
- CGEN $27,589,000.00
- Revenue This Year
- PBYI N/A
- CGEN N/A
- Revenue Next Year
- PBYI N/A
- CGEN $173.80
- P/E Ratio
- PBYI $4.40
- CGEN N/A
- Revenue Growth
- PBYI 2.68
- CGEN N/A
- 52 Week Low
- PBYI $2.23
- CGEN $1.13
- 52 Week High
- PBYI $4.13
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- PBYI 50.17
- CGEN 54.29
- Support Level
- PBYI $3.38
- CGEN $1.65
- Resistance Level
- PBYI $3.70
- CGEN $1.83
- Average True Range (ATR)
- PBYI 0.18
- CGEN 0.10
- MACD
- PBYI -0.03
- CGEN -0.01
- Stochastic Oscillator
- PBYI 35.82
- CGEN 47.50
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.